#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small cell lung cancer recurrent Lennox-Gastaut syndrome Acute myeloid leukaemia recurrent IgA nephropathy Bladder cancer Acquired haemophilia Diabetes insipidus Necrotising myositis Chondrodystrophy Exudative retinopathy Angiosarcoma Congenital myopathy Breast angiosarcoma Congenital nephrogenic diabetes insipidus Mantle cell lymphoma stage III More trials…

    Learn about Rare Diseases

    Brain stem glioma – Diagnostics Idiopathic inflammatory myopathy Glycogen storage disease type V – Basic Information Bronchopulmonary dysplasia – Life with Disease Hereditary ataxia – Trials in Disease Lymphangiosarcoma – Diagnostics Hypereosinophilic syndrome – Treatment Antithrombin III deficiency – Basic Information Systemic mastocytosis – Trials in Disease Paroxysmal nocturnal haemoglobinuria – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Elezanumab Human Immunoglobulin G Rituximab Benzocaine Tulisokibart Tildacerfont Dexibuprofen Salmeterol Xinafoate Exagamglogene Autotemcel Bi-1910 Art0380 Mesilate Florbetaben (18F) Fusidic Acid Cobimetinib Vgl101 IADADEMSTAT Octreotide Sitravatinib Malate Elritercept Ethanol (96 Per Cent) More therapies…

    Learn about Your Condition

    Delayed graft function Haemoptysis Cortical dysplasia Spinal muscular atrophy Ischaemic stroke Ovarian cancer metastatic Diabetic retinal oedema Cardiac disorder Vasoplegia syndrome Pleomorphic leiomyosarcoma Facial paresis Perineal injury Urinary tract infection Graft infection Retinoblastoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Gastroenterologische Gemeinschaftspraxis Herne

Gastroenterologische Gemeinschaftspraxis Herne

Wiescherstraße 20, Herne, 44623, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9
  • Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Risankizumab
    • Vedolizumab
    Austria Bulgaria Croatia Czechia Estonia Finland +14
  • Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary biliary cholangitis
    Investigated Drugs:
    • Seladelpar
    Austria Belgium Czechia France Germany Greece +6

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!